To be fair, they can’t hurry the finish of a trial. Once the FDA asked them for more data they were stuck waiting for a certain number of events before they could analyse the data.
I’ve heard some people suggest that Oxford was the problem. They did all the early work in their first phase 3’s which turned out to be a shambles (not enough elderly, inconsistent dose, inconsistent dose interval) but AZ were involved by the time these US studies were set up, which have been much better designed and run.
Where AZ have shat the bed is with their communications. Press releases full of misleading claims, poorly explained and communicated supply issues etc
Anyway, I’m still convinced it’s a good vaccine. With solid evidence that it’s doing what it’s supposed to do in real life clinical practice. But yeah, hard not to wonder how this all worked out in a parallel universe where Hancock didn’t block the Merck partnership. Merck have loads of experience developing vaccines. AZ have none and it shows.